Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro

Summary

The rate of thrombolysis markedly decreases after a thrombosed vessel is partly recanalized and the remaining clot poses serious risk for rethrombosis. We studied in vitro how thrombolysis depends on penetration of plasma containing thrombolytic agents – 0.2 μg/ml rt-PA or 250 IU/ml streptokinase (SK) nd the magnetic resonance contrast agent Gd-DTPA (at 1 mmol/l) into non-occlusive clots under conditions of fast (turbulent) or slow (laminar) axially directed flow. Cylindrical non-retracted (fresh) or retracted (aged) whole blood clots were pierced lengthways and connected to a perfusion system. Dynamical spin-echo MRI was used for measuring the penetration of labeled plasma into clots and for assessing the remaining clot size. In both types of clots fast flow enhanced the penetration of Gd-DTPA-labeled plasma into clots in comparison to slow flow. In non-retracted clots, lysis with rt-PA and to a lesser extent also lysis with SK followed the path of plasma penetration into clots. After 40 minutes of fast axially directed flow rt-PA resulted in almost complete lysis and SK left only about a third of the clot undissolved, whereas with slow flow lysis was much slower (undissolved clot: 86 ± 5 % with rt-PA and 95 ± 1 % with SK). In retracted clots, substantial lysis was possible only with rt-PA and rapid flow (53 ± 28% of the clot undissolved after 60 min), whereas the use of SK or slow flow precluded meaningful lysis. We conclude that rapid (turbulent) axially directed flow of plasma along non-occlusive blood clots causes forceful exchange of serum inside the clot with outer plasma which enhances both fibrin-specific and non-fibrin-specific lysis of fresh clots. Dissolution of non-occlusive retracted (aged) clots occurs only under fibrin-specific conditions combined with adequate transport of rt-PA into clots.

Keywords

Flow - turbulent - thrombolysis - blood clots

• References

• 1 Del Zoppo GJ. Antithrombotic treatments in acute ischemic stroke. Thromb Haemost 1999; 82: 938-946.
• 2 Meschia JF, Miller DA, Brott TG. Thrombolytic treatment of acute ischemic stroke. Mayo Clin Proc 2002; 77: 542-51.
• 3 Ringleb PA, Schellinger PD, Schranz C. et al. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke. useful or harmful?. Stroke 2002; 33: 1437-41.
• 4 Konstantinides S, Geibel A, Heusel G. et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-50.
• 5 Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med 2002; 347: 1131-2.
• 6 Kandarpa K. Catheter-directed thrombolysis of peripheral arterial occlusions and deep vein thrombosis. Thromb Haemost 1999; 82: 987-96.
• 7 Pislaru SV, Van de Werf F. The current role of thrombolytic therapy in the treatment of acute myocardial infarction. Fibrinolysis & Proteolysis 1999; 13: 91-8.
• 8 Blinc A, Francis CW. Transport Processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost 1996; 76: 481-91.
• 9 Zidansek A, Blinc A. The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases. Thromb Haemost 1991; 65: 553-9.
• 10 Zidansek A, Blinc A, Lahajnar G. et al. Finger-like patterns of blood clots. Biophys J 1995; 69: 803-9.
• 11 Blinc A, Planinsic G, Keber D. et al. Dependence of blood clot lysis on the mode of transport of urokinase into the clot magnetic resonance imaging study in vitro. Thromb Haemost 1991; 65: 549-52.
• 12 Blinc A, Kennedy SD, Bryant RG. et al. Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 1994; 71: 230-5.
• 13 Blinc A, Keber D, Lahajnar G. et al. Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots – a magnetic resonance imaging study in vitro . Thromb Haemost 1992; 68: 667-71.
• 14 Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J 1993; 65: 2622-43.
• 15 Anand S, Diamond SL. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction. Circulation 1996; 94: 763-74.
• 16 Anand S, Kudallur V, Pitman EB. et al. Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion. Ann Biomed Eng 1997; 25: 964-74.
• 17 Bugelski PJ, Kopia GA, Kopaciewicz L. et al. Ultrastructural analysis of thrombolysis by streptokinase and tissue-type plasminogen activator of experimental coronary arterial thrombosis. Fibrinolysis 1989; 03: 137-45.
• 18 Nishino N, Scully MF, Rampling MW. et al. Properties of thrombolytic agents in vitro using a perfusion circuit attaining shear stress at physiological levels. Thromb Haemost 1990; 64: 550-5.
• 19 Komorowicz E, Kolev K, Lerant I. et al. Flow rate-modulated dissolution of fibrin with clotembedded and circulating proteases. Circ Res 1998; 82: 1102-8.
• 20 Sakharov DV, Rijken DC. The effect of flow on lysisis of plasma clots in a plasma environment. Thromb Haemost 2000; 83: 469-74.
• 21 Sabovic M, Lijnen HR, Keber D. et al. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemost 1990; 64: 450-4.
• 22 Carr ME, Shen LL, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16: 1-15.
• 23 Friberger P, Knoss M. Plasminogen determination in human plasma. In: Chromogenic peptide substrates. Scully M, Kakkar VV. Edinburgh: Churchill Livingstone; 1979: 128-39.
• 24 Sabovic M, Lijnen HR, Keber D. et al. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989; 62: 1083-7.
• 25 Martin GV, Kennedy JW, Marder VJ. Thrombolytic therapy for coronary artery disease. In: Colman RC, Hirsch J, Marder VJ, Salzman E. Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia: JB Lippincitt Co; 1994: 1409-37.
• 26 Available at: http://www.schering.com.tr/english/files/Magnevistflakon-yb.doc
• 27 Carr ME, Hardin CL. Fibrin has larger pores when formed in the presence of erythrocytes. Am J Physiol 1987; 253: H1069-73.
• 28 Turitto VT, Baumgartner HR. Initial deposition of platelets and fibrin on vascular surfaces in flowing blood. In: Colman RV, Hirsch J, Marder VJ, Salzman EW. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott Co; 1994: 805-22.
• 29 Dryden HL, Murnaghan FD, Bateman H. Hydrodynamics. New York: Dover Publications; 1956
• 30 Physical factors which influence vascular flow. In: Wright S, Keele CA, Neil E, Joels N. Samson Wright’s Applied Physiology. Oxford: Oxford University Press; 1982: 76-81.
• 31 Klabunde RE. Cardiovascular physiology concepts. Available at: htpp://www.cvphysiology.com/Hemodynamics/H007.htm
• 32 Dawson DL, Strandness DE. Duplex scanning. In: Strandness DE, Van Breda A. Vascular diseases. Surgical and interventional therapy. New York: Churchill Livingstone; 1994: 157-200.
• 33 The GUSTO angiographic investigators. The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
• 34 Zeymer U, Tebbe U, Essen R. et al. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. Am Heart J 1999; 137: 34-8.